Table of Content

1. Introduction To Peptide Drug Conjugates
1.1 Overview
1.2 History & Evolution
1.3 Peptide Drug Conjugates v/s Antibody Drug Conjugates


2. Peptide Drug Conjugates – Structural Components & Mechanism of Action
2.1 Components
2.2 Mechanism of Action


3. Peptide Drug Conjugates Research & Development Trends By Indication
3.1 Cancer
3.2 Others


4. Global Peptide Drug Conjugates Research & Market Trends By Region
4.1 US
4.2 China
4.3 Japan
4.4 Europe
4.5 South Korea


5. Global Peptide Drug Conjugates Market Outlook
5.1 Current Clinical & Market Trends
5.2 Future Market Outlook & Opportunities


6. Peptide Drug Conjugate Development Proprietary Technologies & Methodologies



7. Global Peptide Drug Conjugates Clinical Pipeline Overview
7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Patient Segment
7.5 By Phase


8. Global Peptide Drug Conjugates Clinical Trials Insight By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III


9. Marketed Peptide Drug Conjugates Clinical Insight


10. Lutathera - Clinical & Commercial Insight
10.1 Overview, Availability & Patent Insight
10.2 Dosage & Price Analysis
10.3 Sales Analysis


11. Pepaxto/Pepaxti - Clinical & Commercial Insight
11.1 Overview, Availability & Patent Insight
11.2 Dosage Analysis
11.3 Sales Analysis


12. Competitive Landscape
12.1 Angiochem
12.2 Avacta
12.3 Bicycle Therapeutics
12.4 Cybrexa Therapeutics
12.5 ITM Solucin
12.6 Novartis
12.7 Oncopeptides
12.8 PepGen Corporation
12.9 Soricimed Biopharma
12.10 Theratechnologies



List of Figures

Figure 1-1: Timeline of Key Events in Development of Peptide Drug Conjugates

Figure 2-1: Peptide Drug Conjugates - Components
Figure 2-2: Peptide Drug Conjugate - Mechanism Of Action

Figure 3-1: Approved Peptide Drug Conjugates
Figure 3-2: TH1902-CTR-0001 Phase I (NCT04706962) Study – Initiation & Completion Year
Figure 3-3: CBX-12-101 Phase I/II (NCT04902872) Study – Initiation & Completion Year
Figure 3-4: CBX-12-201 Phase II (NCT06315491) Study – Initiation & Completion Year
Figure 3-5: Duravelo-1 Phase I/II (NCT04561362) Study – Initiation & Completion Year
Figure 3-6: Duravelo-2 Phase II/III (NCT06225596) Study – Initiation & Completion Year
Figure 3-7: Duravelo-3 Phase II (NCT06840483) Study – Initiation & Completion Year
Figure 3-8: Duravelo-4 Phase II (NCT06933329) Study – Initiation & Completion Year
Figure 3-9: BT5528-100 Phase I/II (NCT04180371) Study – Initiation & Completion Year
Figure 3-10: ALS-6000-101 Phase I (NCT04969835) Study – Initiation & Completion Year

Figure 5-1: Global – Peptide drug Conjugates Market (US$ Million), 2018-2025
Figure 5-2: Global – Peptide drug Conjugates Market (US$ Million), 2025-2030
Figure 5-3: Potential Future Directions in Peptide-Drug Conjugate Development

Figure 6-1: Alphalex Platform - Cybrexa
Figure 6-2: Decoy Platform - Candidate Life Cycle
Figure 6-3: Decoy Platform - Modular Peptide Engineering & Conjugation Chemistry
Figure 6-4: Decoy Platform - Features
Figure 6-5: EDO Platform - Drug Structure
Figure 6-6: OncoPDCs – Excellamol
Figure 6-7: PDPS Platform - PeptiDream
Figure 6-8: Rational Design Based Drug Discovery - Mainline Biosciences
Figure 6-9: pre|CISION? Platform – Generations & Features
Figure 6-10: PIP - Mechanism of Action
Figure 6-11: PIP Platform - TwoStep Toolbox
Figure 6-12: Peptide - Advantages
Figure 6-13: SORT1+ Technology – PDC Structure
Figure 6-14: MPD-1 - Mechanism of Action
Figure 6-15: Bi-XDC Technology - Coherent Biopharma
Figure 6-16: NIPEP-TPP - NIBEC

Figure 7-1: Global - Peptide Drug Conjugate Clinical Pipeline by Company (Number of Drugs), 2025 Till 2030
Figure 7-2: Global - Peptide Drug Conjugate Clinical Pipeline by Country (Number of Drugs), 2025 Till 2030
Figure 7-3: Global - Peptide Drug Conjugate Clinical Pipeline by Indication (Number of Drugs), 2025 Till 2030
Figure 7-4: Global - Peptide Drug Conjugate Clinical Pipeline by Patient Segment (Number of Drugs), 2025 Till 2030
Figure 7-5: Global - Peptide Drug Conjugate Clinical Pipeline by Phase (Number of Drugs), 2025 Till 2030

Figure 10-1: Lutathera – Approval Year by Region
Figure 10-2: Lutathera – Patent Filing & Expiration Year
Figure 10-3: Global – Lutathera Sales (US$ Million), 2018-2025
Figure 10-4: Global – Lutathera Quarterly Sales (US$ Million), 2025
Figure 10-5: Regional – Lutathera Sales (US$ Million), Q1’2025
Figure 10-6: Regional – Lutathera Sales (US$ Million), Q1’2025
Figure 10-7: Global – Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-8: US – Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-9: US – Lutathera Sales (US$ Million), 2023-2025
Figure 10-10: ROW – Lutathera Quarterly Sales (US$ Million), 2024
Figure 10-11: ROW – Lutathera Sales (US$ Million), 2023-2025

Figure 11-1: Pepaxto/Pepaxti – Approval Year by Region
Figure 11-2: Pepaxti – Patent Filing & Expiration Year
Figure 11-3: Europe – Pepaxti Sales (US$ Million), 2021-2025

List of Tables

Table 1-1: Antibody Drug Conjugates v/s Peptide Drug Conjugates

Table 10-1: Lutathera – Recommended Amino Acid Solution Dosing
Table 10-2: Lutathera - Recommended Dosage Modifications for Adverse Reactions

Table 11-1: Pepaxti - Recommended Dose Reduction for Adverse Reactions
Table 11-2: Pepaxti - Recommended Dose Modifications for Adverse Reactions